Saerum recruited to speed Lundbeck's CNS drug research
UK-based drug discovery business, Sareum Holdings, has entered into a second 12 month collaborative agreement with H. Lundbeck of Copenhagen, Denmark, to provide protein structure determination capabilities to accelerate the international pharmaceutical company\'s drug discovery.
UK-based drug discovery business, Sareum Holdings, has entered into a second 12 month collaborative agreement with H. Lundbeck of Copenhagen, Denmark, to provide protein structure determination capabilities to accelerate the international pharmaceutical company's drug discovery.
Sareum will provide high throughput protein expression, purification and structure determination to help Lundbeck develop therapeutics designed to treat diseases of the central nervous system. Sareum will receive research fees and success milestone payments but the financial terms of the agreement were not disclosed.
Sareum's approach to drug discovery relies on knowledge of the 3D structure of the proteins that cause disease. Once the structure is known, potential drugs can be designed to 'lock-in' to the protein and reverse or arrest the disease.
"Structure-based drug design is an important part of a modern drug discovery strategy, and we look forward to using this broadened collaboration with Sareum to enhance the success of our drug discovery process," said Lundbeck's vice-president of research, Dr Klaus Peter Bogeso.